Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kohei Mizuta

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
In Vivo (Athens, Greece)|April 30, 2024
Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse ModelMotokazu Sato, Kohei Mizuta, Qinghong Han, et al.
Anticancer Research|July 26, 2024
Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant FibrosarcomaSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|October 30, 2024
Accurate and Safe Tumor Targeting of Orally-administered <i>Salmonella typhimurium</i> A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude MiceSei Morinaga, Ming Zhao, Kohei Mizuta, et al.
Anticancer Research|February 29, 2024
Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal FibroblastsSei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Anticancer Research|April 28, 2025
Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal FibroblastsYohei Asano, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|May 31, 2024
DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal FibroblastsSei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Cancer Diagnosis & Prognosis|May 5, 2025
Perspective on an Innovative Curative Strategy for Peritoneal Metastasis Involving Peritonectomy, Hyperthermic Intraperitoneal Chemotherapy, and Adjuvant Chemotherapy Identified as Effective in the Histoculture Drug Response Assay (HDRA)Yohei Asano, Yutaka Yonemura, Chihiro Hozumi, et al.
Anticancer Research|October 28, 2025
Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal FibroblastsYohei Asano, Qinghong Han, Shukuan Li, et al.
Anticancer Research|October 28, 2025
Very Rapid Eradication of a Large Squamous-Cell Carcinoma of the Head and Neck Treated With First-line Combination Chemotherapy, a Low-methionine Diet, and Oral Recombinant MethioninaseYohei Asano, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal FibroblastsYohei Asano, Qinghong Han, Shukuan Li, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
In Vivo (Athens, Greece)|April 30, 2024
Targeting Methionine Addiction Combined With Low-dose Irinotecan Arrested Colon Cancer in Contrast to High-dose Irinotecan Alone, Which Was Ineffective, in a Nude-mouse ModelMotokazu Sato, Kohei Mizuta, Qinghong Han, et al.
Anticancer Research|July 26, 2024
Recombinant Methioninase Is Selectively Synergistic With Doxorubicin Against Wild-type Fibrosarcoma Cells Compared to Normal Cells and Overcomes Highly-Doxorubicin-resistant FibrosarcomaSei Morinaga, Qinghong Han, Kohei Mizuta, et al.
In Vivo (Athens, Greece)|October 30, 2024
Accurate and Safe Tumor Targeting of Orally-administered <i>Salmonella typhimurium</i> A1-R Leads to Regression of an Aggressive Fibrosarcoma in Nude MiceSei Morinaga, Ming Zhao, Kohei Mizuta, et al.
Anticancer Research|February 29, 2024
Extensive Synergy Between Recombinant Methioninase and Eribulin Against Fibrosarcoma Cells But Not Normal FibroblastsSei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Anticancer Research|April 28, 2025
Recombinant Methioninase and Cisplatinum Act Synergistically to Inhibit Lewis Lung Carcinoma Cells But Not Normal FibroblastsYohei Asano, Qinghong Han, Kohei Mizuta, et al.
Anticancer Research|May 31, 2024
DNA-Binding Agent Trabectedin Combined With Recombinant Methioninase Is Synergistic to Decrease Fibrosarcoma Cell Viability and Induce Nuclear Fragmentation But Not Synergistic on Normal FibroblastsSei Morinaga, Qinghong Han, Yutaro Kubota, et al.
Cancer Diagnosis & Prognosis|May 5, 2025
Perspective on an Innovative Curative Strategy for Peritoneal Metastasis Involving Peritonectomy, Hyperthermic Intraperitoneal Chemotherapy, and Adjuvant Chemotherapy Identified as Effective in the Histoculture Drug Response Assay (HDRA)Yohei Asano, Yutaka Yonemura, Chihiro Hozumi, et al.
Anticancer Research|October 28, 2025
Triple Combination of Recombinant Methioninase and the Anti-parasitic Drugs Ivermectin, and Chloroquine Selectively Eradicates Pancreatic Cancer Cells While Sparing Normal FibroblastsYohei Asano, Qinghong Han, Shukuan Li, et al.
Anticancer Research|October 28, 2025
Very Rapid Eradication of a Large Squamous-Cell Carcinoma of the Head and Neck Treated With First-line Combination Chemotherapy, a Low-methionine Diet, and Oral Recombinant MethioninaseYohei Asano, Qinghong Han, Shukuan Li, et al.
Anticancer Research|November 29, 2025
Selective Synergy of the Combination of Recombinant Methioninase With Cisplatinum and Ivermectin Which Eradicates Lung-Cancer Cells but Has No Synergy and Limited Effect on Normal FibroblastsYohei Asano, Qinghong Han, Shukuan Li, et al.
Pageof 8